🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

154 results for “matching” Clear

  1. ALXN2420, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, matching placebo for ALXN2420, LANREOTIDE ACETATE, OCTREOTIDE ACETATE

    Alexion Europe SAS

    Acromegaly

    phase 2 small molecule active

    1 trial

  2. AP1189 Tablet, AP1189 Tablet, AP1189 Tablet, Matching Placebo (tablets), Methotrexat-Ebewe, 2,5 mg, tabletki

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  3. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 2 small molecule active

    1 trial

  4. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Alopecia areata

    phase 2 small molecule active

    1 trial

  5. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Coeliac disease

    phase 2 small molecule active

    1 trial

  6. Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

    Acumen Pharmaceuticals

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial

  7. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  8. BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  9. BI 3000202, BI 3000202, Placebo matching BI 3000202

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  10. BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374

    Boehringer Ingelheim

    clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease

    phase 2 small molecule active

    1 trial

  11. BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

    Boehringer Ingelheim

    chronic kidney disease

    phase 2 small molecule active

    1 trial

  12. Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

    AstraZeneca

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  13. Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  14. CRD-4730, CRD-4730 matching placebo

    Lacuna Pharma Pty Ltd

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 2 small molecule active

    1 trial

  15. DNTH103, Matching placebo to DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial

  16. Daridorexant matching placebo, QUVIVIQ 50 mg film-coated tablets, QUVIVIQ 25 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 2 small molecule active

    1 trial

  17. Description and Composition of the Placebo • Placebo oil solution matching the Cannabis Extract Avextra 10/10 Solution. • Pharmaceutical form: solution (oil) • Route of administration: oral • Storage: Store tightly closed below 25°C and protected from light like the verum form. • Country of origin: Italy., Cannabis Extract Avextra 10/10 Solution

    Fondazione Telethon ETS

    Patients with advanced oncologic disease receiving active treatment with WHO level II or III opioids and adjuvants therapies

    phase 2 small molecule active

    1 trial

  18. Galvokimig, Placebo matching Test 0.9% sodium chloride solution for injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  19. IDOR-1117-2520 matching placebo

    Lacuna Pharma Pty Ltd

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial

  20. KT-621, KT-621, KT-621, The placebo is used in the Double-blind, Placebo-controlled (DBPC) Treatment Period. Participants are randomly assigned to receive either KT-621 or a matching placebo. The placebo is designed to match the study drug in appearance and administration method to maintain blinding.

    Kymera Therapeutics

    Moderate to Severe Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  21. Matching Placebo

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  22. Matching Placebo for Test, SAR443765 / LUNSEKIMIG

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  23. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  24. Matching film-coated placebo tablet

    Bioprojet Pharma

    Obsessive compulsive disorder

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources